Skip to content

Zymeworks ZYME Free cash flow margin

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Amgen logo
AmgenAMGN
23.1%-8.9pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
1.9%+1.0pp
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-238.9%-90.9pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-428.4%-214pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
36.2%+18.4pp

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Calculated from Zymeworks’s reported figures.

Based on trailing twelve months.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's free cash flow margin?
Zymeworks (ZYME) reported free cash flow margin of -94.8% in Q1 2026.
How has Zymeworks's free cash flow margin changed year-over-year?
Zymeworks's free cash flow margin decreased by 14.1% year-over-year, from -83.1% to -94.8%.
What is the long-term trend for Zymeworks's free cash flow margin?
Over 3 years (2020 to 2025), Zymeworks's free cash flow margin has grown at a -56.6% compound annual growth rate (CAGR), from -399.8% to -32.6%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.